DEXA Body Composition: Longevity-Medicine Target Ranges Explained

What Does a DEXA Body Composition Scan Actually Measure?

A DEXA scanner directs two low-energy X-ray beams at different kilovoltages through every tissue in the body. Because fat, lean tissue, and bone absorb photons differently, the software reconstructs regional compartments: total fat mass, lean soft tissue, bone mineral content, and, on modern scanners, visceral adipose tissue as a separate estimate.

The Four Outputs That Matter Clinically

The four numbers a longevity clinician reviews first are: (1) appendicular lean mass index (ALMI), calculated as arms-plus-legs lean mass divided by height squared; (2) total body fat percentage; (3) visceral adipose tissue area in cm²; and (4) lumbar and femoral bone mineral density expressed as a T-score.

Each compartment carries distinct mortality risk. A 2018 meta-analysis of 22 prospective cohorts (N=168,916) found that low muscle mass independently increased all-cause mortality risk by 23% after adjusting for fat mass, confirming that the two compartments carry separate prognostic weight 1.

Why Standard BMI Misses the Point

Body mass index conflates every tissue into one ratio. Two men at identical BMI of 27 can differ by 10 percentage points in body fat and by 3 kg/m² in ALMI. The Framingham Heart Study extension data showed that "normal-weight obesity", normal BMI with elevated fat percentage, was associated with a 2.4-fold higher cardiovascular mortality rate compared to metabolically healthy individuals at the same BMI 2. DEXA resolves this ambiguity in a single scan.

DEXA also separates subcutaneous fat from visceral fat. Subcutaneous fat at the thigh actually correlates with better insulin sensitivity in some analyses; visceral fat, by contrast, is metabolically active, secreting pro-inflammatory adipokines that drive insulin resistance and atherogenesis 3.

Visceral Adipose Tissue: The Longevity Target Range

Visceral adipose tissue (VAT) is the single DEXA compartment with the strongest evidence base for cardiovascular and metabolic endpoints. The longevity-medicine consensus target is VAT area below 100 cm², with many aggressive protocols targeting below 80 cm².

Why 100 cm² Is the Key Threshold

The Dallas Heart Study (N=2,831) demonstrated that VAT area above 100 cm² on abdominal CT, the gold-standard modality that DEXA VAT estimates are calibrated against, was associated with a 2-fold increase in metabolic syndrome prevalence and a significant rise in coronary artery calcium scores 4. DEXA VAT area correlates with CT VAT at r=0.80 to 0.87 across validation studies, making it an acceptable surrogate in clinical practice 5.

Sex Differences in VAT Thresholds

Men accumulate VAT more readily and typically carry higher absolute VAT than premenopausal women at equivalent body fat percentages. After menopause, estrogen withdrawal accelerates visceral depot expansion; postmenopausal women can reach VAT areas that rival men with the same waist circumference. The Endocrine Society's 2022 obesity pharmacotherapy guidelines note that waist circumference thresholds for cardiometabolic risk differ by sex (greater than 102 cm in men, greater than 88 cm in women), a pattern mirrored in DEXA VAT distribution data 6.

Tracking VAT During GLP-1 Therapy

Semaglutide 2.4 mg (Wegovy) preferentially reduces visceral fat. In STEP-1 (N=1,961), participants receiving semaglutide lost 14.9% mean body weight versus 2.4% on placebo at 68 weeks (P<0.001) 7. Body composition sub-studies of GLP-1 receptor agonists consistently show that roughly 25 to 35% of total weight lost comes from lean mass if resistance training is absent, a ratio that makes serial DEXA monitoring every 12 to 16 weeks clinically necessary during active titration.

Lean Mass and Appendicular Lean Mass Index: Targets and Thresholds

Lean mass preservation is the central challenge of GLP-1-era weight management. Losing significant lean mass accelerates functional decline, reduces resting metabolic rate, and raises fracture risk, none of which appear in the scale weight.

ALMI Diagnostic Thresholds for Sarcopenia

The Foundation for the National Institutes of Health (FNIH) Sarcopenia Project established sex-specific ALMI thresholds using DEXA data from nine population cohorts. Sarcopenia is defined at ALMI below 7.0 kg/m² in men and below 5.5 kg/m² in women 8. These cutoffs correspond to the lower fifth percentile of younger reference populations and predict mobility limitation and falls in older adults.

The European Working Group on Sarcopenia in Older People (EWGSOP2) updated its definition in 2019 to require both low muscle quantity (ALMI below these thresholds) and low muscle strength (grip strength below 27 kg in men, 16 kg in women) for a confirmed diagnosis 9.

Longevity-Medicine Lean Mass Targets (Not Just "Not Sarcopenic")

Avoiding a sarcopenia diagnosis is the floor, not the ceiling. In longevity medicine, the practical target for men is ALMI above 8.0 kg/m² and for women above 6.0 kg/m², keeping individuals well above the diagnostic threshold with a buffer to accommodate natural age-related attrition of 0.5 to 1.0% of muscle mass per year after age 50 10.

Resistance training three or more sessions per week, combined with protein intake of 1.6 to 2.2 g/kg of body weight per day, is the only intervention with consistent evidence for increasing ALMI in adults over 50. A 2017 Cochrane review of 121 randomized controlled trials (N=6,700) confirmed that progressive resistance training increases lean mass by a mean of 1.1 kg and increases muscle strength by 25 to 30% in older adults 11.

Lean Mass Monitoring During GLP-1 and Peptide Protocols

Ipamorelin/CJC-1295 combinations and tesamorelin are sometimes added to GLP-1 regimens specifically to mitigate lean mass loss. Tesamorelin, an FDA-approved growth hormone-releasing hormone analogue, reduced VAT by 18% over 26 weeks in HIV-associated lipodystrophy trials and modestly increased trunk lean mass 12. Serial DEXA at baseline and every 12 to 16 weeks allows the clinician to quantify whether the lean-mass-to-fat-mass ratio is improving or whether the protein and training prescription needs adjustment.

The HealthRX clinical team uses the following four-variable DEXA review framework at each follow-up visit:

1. ALMI trend (target: stable or increasing; flag if drop exceeds 0.3 kg/m² per interval)
2. VAT area trend (target: below 100 cm²; flag if plateau despite weight loss)
3. Body fat percentage trajectory (target: moving toward sex-specific range)
4. Bone mineral density T-score (target: above −1.0; refer if crossing −2.5)

Body Fat Percentage: What "Optimal" Means in Longevity Medicine

Total body fat percentage is the most commonly cited DEXA output, but interpreting it requires age and sex stratification. A body fat percentage of 25% means something different at age 30 versus age 65.

Sex-Specific and Age-Stratified Reference Ranges

The American College of Sports Medicine (ACSM) classifies body fat as follows for adults: men aged 20 to 39 are considered "fitness" range at 8 to 19%, with above 25% classified as obese; women aged 20 to 39 are "fitness" range at 21 to 32%, obese above 39% 13. These classifications shift upward with age because some increase in adiposity is physiologically expected.

Longevity-medicine targets are tighter than population norms. The practical targets used in evidence-based longevity protocols are 10 to 20% for men and 18 to 28% for women across the 40 to 70 age decade, with the lower end of each range reserved for individuals who maintain adequate ALMI.

The "Fat But Fit" Paradox and Why DEXA Resolves It

Cardiorespiratory fitness can partially offset elevated fat mass risk, but the protective effect attenuates above roughly 30% body fat in men and 38% in women. Below those levels, fit individuals at moderately elevated body fat percentages carry lower cardiovascular event rates than unfit individuals at normal fat percentages, a finding from the Aerobics Center Longitudinal Study (N=43,265) 14. DEXA gives the clinician enough granularity to distinguish benign from hazardous fat distributions and to track changes over time.

Regional Fat Patterns: Android vs. Gynoid Ratio

Modern DEXA software reports an android-to-gynoid fat ratio, with the android region centered on the abdomen and the gynoid on the hips and thighs. An android/gynoid ratio above 1.0 correlates with insulin resistance, elevated triglycerides, and hypertension. A ratio below 0.85 in men and below 0.75 in women suggests a more metabolically favorable fat distribution 15.

Bone Mineral Density: The Forgotten Longevity Metric

Bone density falls off the radar in body composition discussions focused on weight loss, yet hip fracture at age 75 carries a 20 to 30% one-year mortality rate. DEXA provides T-scores and Z-scores at the lumbar spine and femoral neck as a routine part of the full-body scan.

Interpreting T-Scores

The World Health Organization classifies bone mineral density as normal at T-score at or above −1.0, osteopenia between −1.0 and −2.5, and osteoporosis at or below −2.5 16. Fracture risk rises exponentially below −2.5, but fracture events also occur in osteopenia, approximately 54% of hip fractures in women occur in the osteopenic range because osteopenic individuals are far more numerous than osteoporotic ones.

The longevity-medicine target is a T-score above −1.0, with intervention considered at −1.5 if other risk factors (smoking, low calcium intake, vitamin D deficiency, or glucocorticoid use) are present. The U.S. Preventive Services Task Force recommends routine DEXA screening for all women aged 65 or older and for younger postmenopausal women with elevated fracture risk 17.

GLP-1 Therapy and Bone Density

Rapid weight loss accelerates bone loss, and GLP-1 receptor agonists are no exception. A 2023 analysis of the SELECT trial (N=17,604) found that semaglutide 2.4 mg was not associated with increased fracture rates over a median 34.2 months of follow-up 18. Nevertheless, the mechanism of unloading the skeleton during weight loss remains a theoretical concern, and measuring bone mineral density at baseline and at 12-month intervals during GLP-1 therapy is standard practice in HealthRX longevity protocols.

Calcium intake of 1,000 to 1,200 mg per day and vitamin D3 supplementation to maintain serum 25-OH-D above 40 ng/mL are the minimum co-interventions recommended alongside GLP-1 therapy in patients at any fracture risk elevation.

Scan Frequency, Protocols, and Practical Considerations

How Often to Repeat DEXA

Scan interval depends on clinical context. The ISCD (International Society for Clinical Densitometry) recommends the following minimum re-scan intervals:

• Pharmacological weight loss (GLP-1, bariatric surgery): every 6 to 12 months for bone density; every 12 to 16 weeks for body composition during active titration
• Resistance training or body recomposition protocols: every 12 to 16 weeks
• Stable maintenance phase: annually

Shorter intervals are unlikely to produce changes exceeding DEXA's least significant change (LSC) for lean mass, which is approximately 0.9 to 1.4 kg depending on scanner model and technologist precision.

Scanner Variability and Cross-Calibration

DEXA results are not directly interchangeable across scanner manufacturers. A patient scanned on a Hologic Horizon will receive different absolute values than on a GE Lunar iDXA for the same body, primarily because the two systems use different reference databases and beam geometry. The ISCD recommends always using the same scanner for longitudinal tracking and performing a cross-calibration scan if a patient changes facilities 19.

Positioning and Hydration Artifacts

Hydration status affects lean mass readings. A 2-liter fluid shift can alter apparent lean mass by 1 to 2 kg. Patients should present adequately hydrated (not over-hydrated or dehydrated from fasting or diuretics) and avoid intense exercise in the 24 hours before scanning to minimize glycogen and water fluctuations in muscle tissue.

DEXA in the Context of GLP-1 Lean Mass Tracking

GLP-1 receptor agonists reduce total body weight reliably, but the composition of that weight loss varies widely. Reported lean mass loss as a fraction of total weight loss ranges from 22% to 39% in GLP-1 trials that used DEXA or BIA for body composition, compared with 10 to 20% for combined diet, resistance training, and adequate protein intake.

Tirzepatide Data

Tirzepatide (Mounjaro/Zepbound), the dual GIP/GLP-1 agonist, produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539, P<0.001 vs. Placebo) 20. DEXA sub-studies showed that lean mass loss was proportionally similar to semaglutide, reinforcing the need for concurrent resistance training and protein optimization regardless of which agent is used.

Practical Protein and Training Benchmarks

The anabolic threshold for muscle protein synthesis is approximately 0.40 g of leucine-rich protein per meal, corresponding to roughly 30 to 40 g of complete protein per sitting. Distributing protein intake across four meals rather than concentrating it in one or two appears to maximize 24-hour muscle protein synthesis based on stable isotope tracer studies 21. DEXA provides the objective endpoint to verify that this prescription is working, not just the subjective report of adherence.

The Endocrine Society's position statement on obesity pharmacotherapy states: "Pharmacological treatment of obesity should be accompanied by lifestyle modification, including dietary counseling and physical activity, to optimize the ratio of fat to lean mass lost during weight loss therapy" 6.

Reference Ranges Summary Table

| Compartment | Sarcopenia / At-Risk Threshold | Longevity Medicine Target | |---|---|---| | ALMI (men) | <7.0 kg/m² | ≥8.0 kg/m² | | ALMI (women) | <5.5 kg/m² | ≥6.0 kg/m² | | VAT area | >160 cm² (high risk) | <100 cm² | | Body fat % (men 40 to 70) | >28% | 10 to 20% | | Body fat % (women 40 to 70) | >38% | 18 to 28% | | Bone T-score | <−2.5 (osteoporosis) | ≥−1.0 | | Android/gynoid ratio (men) | >1.0 | <0.85 | | Android/gynoid ratio (women) | >0.90 | <0.75 |